CCM
REGN icon

Coldstream Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Coldstream Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$863K Sell
1,384
-490
-26% -$334K 0.01% 531
2026
Q1 		$1.45M Buy
1,874
+27
+1% +$20.7K 0.02% 374
2025
Q4 		$1.43M Sell
1,847
-180
-9% -$122K 0.02% 364
2025
Q3 		$1.14M Buy
2,027
+933
+85% +$528K 0.02% 422
2025
Q2 		$574K Sell
1,094
-244
-18% -$136K 0.01% 600
2025
Q1 		$849K Buy
1,338
+27
+2% +$18.6K 0.02% 414
2024
Q4 		$934K Buy
1,311
+2
+0.2% +$1.68K 0.02% 396
2024
Q3 		$1.36M Buy
1,309
+60
+5% +$66.8K 0.03% 302
2024
Q2 		$1.31M Buy
1,249
+65
+5% +$63K 0.03% 275
2024
Q1 		$1.14M Buy
1,184
+1
+0.1% +$951 0.03% 299
2023
Q4 		$1.04M Buy
1,183
+4
+0.3% +$3.29K 0.03% 286
2023
Q3 		$970K Buy
1,179
+8
+0.7% +$6.29K 0.03% 266
2023
Q2 		$841K Sell
1,171
-33
-3% -$25.4K 0.03% 297
2023
Q1 		$989K Buy
1,204
+36
+3% +$27.2K 0.03% 275
2022
Q4 		$843K Buy
+1,168
New +$862K 0.03% 291
2022
Q2 		$559K Sell
945
-3
-0.3% -$1.95K 0.02% 358
2022
Q1 		$662K Buy
948
+61
+7% +$38.6K 0.02% 303
2021
Q4 		$560K Buy
887
+475
+115% +$292K 0.02% 387
2021
Q3 		$231K Sell
412
-87
-17% -$54K 0.01% 358
2021
Q2 		$279K Buy
+499
New +$253K 0.01% 409
2021
Q1 		– Sell
-460
Closed -$222K – 458
2020
Q4 		$222K Buy
+460
New +$248K 0.01% 366
2020
Q3 		– Sell
-341
Closed -$213K – 325
2020
Q2 		$213K Buy
+341
New +$194K 0.02% 282
2015
Q4 		– Sell
-540
Closed -$251K – 215
2015
Q3 		$251K Sell
540
-5
-0.9% -$2.69K 0.07% 138
2015
Q2 		$278K Buy
+545
New +$266K 0.07% 132
2015
Q1 		– Sell
-545
Closed -$224K – 171
2014
Q4 		$224K Buy
+545
New +$214K 0.06% 152

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Coldstream Capital Management's REGN Position: Q2 2026 in Review

Coldstream Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 26% in Q2 2026, selling an estimated $334K and leaving 1,384 shares worth $863K. The position accounts for 0.01% of the portfolio, ranked #531.

Coldstream Capital Management first reported a position in REGN in Q4 2014 and has held it in 25 quarters since. The position peaked at $1.45M in Q1 2026. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Coldstream Capital Management held 1,384 shares of Regeneron Pharmaceuticals worth $863K as of Q2 2026.
  • Coldstream Capital Management sold 490 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $334K.
  • Regeneron Pharmaceuticals made up 0.01% of Coldstream Capital Management's portfolio in Q2 2026, its #531 holding.
  • Coldstream Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2014 and has held it in 25 quarters since.
  • Coldstream Capital Management's Regeneron Pharmaceuticals position peaked at $1.45M in Q1 2026.
  • 1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Coldstream Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.